In situ conversion of defective Treg into SuperTreg cells to treat advanced IPEX-like disorders in mice

Yongqin Li, Yuxin Chen, Shaoshuai Mao, Ravinder Kaundal, Zhengyu Jing, Qin Chen, Xinxin Wang, Jing Xia, Dahai Liu, Jianlong Sun, Haopeng Wang and Tian Chi ()
Additional contact information
Yongqin Li: School of Life Sciences and Technology, Shanghai Tech University
Yuxin Chen: School of Life Sciences and Technology, Shanghai Tech University
Shaoshuai Mao: School of Life Sciences and Technology, Shanghai Tech University
Ravinder Kaundal: Deptartment Immunobiology, Yale University School of Medicine
Zhengyu Jing: School of Life Sciences and Technology, Shanghai Tech University
Qin Chen: School of Life Sciences and Technology, Shanghai Tech University
Xinxin Wang: School of Life Sciences and Technology, Shanghai Tech University
Jing Xia: School of Life Sciences and Technology, Shanghai Tech University
Dahai Liu: Department of Basic Medicine and Biomedical Engineering, School of Stomatology and Medicine, Foshan University
Jianlong Sun: School of Life Sciences and Technology, Shanghai Tech University
Haopeng Wang: School of Life Sciences and Technology, Shanghai Tech University
Tian Chi: School of Life Sciences and Technology, Shanghai Tech University

Nature Communications, 2020, vol. 11, issue 1, 1-12

Abstract: Abstract Mutations disrupting regulatory T (Treg) cell function can cause IPEX and IPEX-related disorders, but whether established disease can be reversed by correcting these mutations is unclear. Treg-specific deletion of the chromatin remodeling factor Brg1 impairs Treg cell activation and causes fatal autoimmunity in mice. Here, we show with a reversible knockout model that re-expression of Brg1, in conjunction with the severe endogenous proinflammatory environment, can convert defective Treg cells into powerful, super-activated Treg cells (SuperTreg cells) that can resolve advanced autoimmunity, with Brg1 re-expression in a minor fraction of Treg cells sufficient for the resolution in some cases. SuperTreg cells have enhanced trafficking and regulatory capabilities, but become deactivated as the inflammation subsides, thus avoiding excessive immune suppression. We propose a simple, robust yet safe gene-editing-based therapy for IPEX and IPEX-related disorders that exploits the defective Treg cells and the inflammatory environment pre-existing in the patients.

Date: 2020
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-020-15836-2 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:11:y:2020:i:1:d:10.1038_s41467-020-15836-2

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-020-15836-2

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().